### HIGHLIGHTS

2387  Selected Articles from This Issue

### COMMENTARY

2389  Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success

Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Housten, Jamie L. Studts, and Laura D. Scherer

2454  Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review

Michael A. Liss, Robin J. Leach, Martin G. Sandy, and Oliver J. Semmes

2463  The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment

Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman

### CEBP FOCUS

2396  The National Cancer Institute Early Detection Research Network: Two Decades of Progress

Sudhir Srivastava and Paul D. Wagner

2401  The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers

Sudhir Srivastava and Paul D. Wagner

2411  Biomarkers for Lung Cancer Screening and Detection

Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash

2416  Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation

Maria Farooq and James G. Herman

2423  Lung Cancer and Immunity Markers

Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett

2431  Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation

Robert S. Bresalier, William M. Grady, Sanford D. Markowitz, Hans Jørgen Nielsen, Surinder K. Batra, and Paul D. Lampe

2441  Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia

Joshua D. Cohen, Brenda Diergaarde, Nickolas Papadopoulos, Kenneth W. Kinzler, and Robert E. Schoen

2454  Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review

Michael A. Liss, Robin J. Leach, Martin G. Sandy, and Oliver J. Semmes

2463  The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment

Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman

2475  Autoantibodies in Early Detection of Breast Cancer

Femina Rauf, Karen S. Anderson, and Joshua LaBaer

2486  Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers

William M. Grady, Ming Yu, Sanford D. Markowitz, and Amitabh Chak

2495  Biomarkers for the Early Detection of Hepatocellular Carcinoma

Nechar D. Parikh, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok

2504  Biomarkers and Strategies for Early Detection of Ovarian Cancer

Robert C. Bast Jr, Zhen Lu, Chae Young Han, Karen H. Lu, Karen S. Anderson, Charles W. Drescher, and Steven J. Skates

2513  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN

Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrmann, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singh, Randall E. Brand, Anirban Maitra, and Brian B. Haab
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2524</td>
<td>Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network</td>
<td>Harvey I. Pass, Marjan Alimi, Michele Carbone, Haining Yang, and Chandra M. Goparaju</td>
</tr>
<tr>
<td>2541</td>
<td>The Potential of Circular RNAs as Cancer Biomarkers</td>
<td>Jason R. Brown and Arul M. Chinnaiyan</td>
</tr>
<tr>
<td>2546</td>
<td>Radiomics Improves Cancer Screening and Early Detection</td>
<td>Robert J. Gillies and Matthew B. Schabath</td>
</tr>
<tr>
<td>2556</td>
<td>Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA</td>
<td>Annie H. Ren, Clare A. Fiala, Eleftherios P. Diamandis, and Vathany Kulasingam</td>
</tr>
<tr>
<td>2575</td>
<td>Adding Rigor to Biomarker Evaluations—EDRN Experience</td>
<td>Ziding Feng and Margaret S. Pepe</td>
</tr>
<tr>
<td>2591</td>
<td>Premature Years of Life Lost Due to Cancer in the United States in 2017</td>
<td>Minkyo Song, Allan Hildesheim, and Meredith S. Shiels</td>
</tr>
<tr>
<td>2599</td>
<td>Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach</td>
<td>Kemal Caglar Gogebackan, Elizabeth G. Berry, Alan C. Geller, Kemal Sonmez, Sancy A. Leachman, and Ruth Etzioni</td>
</tr>
<tr>
<td>2617</td>
<td>Associations of Leisure-Time Physical Activity and Television Viewing with Life Expectancy Cancer-Free at Age 50: The ARIC Study</td>
<td>Carmen C. Cuthbertson, Hazel B. Nichols, Xianming Tan, Anna Kucharska-Newton, Gerardo Heiss, Corinne E. Joshu, Elizabeth A. Platz, and Kelly R. Evenson</td>
</tr>
<tr>
<td>2624</td>
<td>Community-Acquired Escherichia coli Bacteremia after Age 50 and Subsequent Incidence of a Cancer Diagnosis: A Danish Population-Based Cohort Study</td>
<td>Kirstine K. Sgaarda, Katalin Veres, Christina M.J.E. Vandebroucke-Grauls, Jan P. Vandebroucke, Henrik T. Sorensen, and Henrik C. Schornheyder</td>
</tr>
<tr>
<td>2633</td>
<td>Low Levels of Alcohol Consumption and Risk of Intestinal Metaplasia: A Cohort Study</td>
<td>Kyungseon Kim, Yoosoo Chang, Jiin Ahn, Hyo-Jooyang, and Seungho Ryu</td>
</tr>
<tr>
<td>2660</td>
<td>Association between Receipt of Guideline-Concordant Lung Cancer Treatment and Individual- and Area-Level Factors: A Spatio-Temporal Analysis</td>
<td>Win Wah, Rob G. Stirling, Susannah Ahern, and Arul Earnest</td>
</tr>
<tr>
<td>2662</td>
<td>HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study</td>
<td>Christina Carlander, Camilla Lahrden, Carina Eklund, Sara Nordqvist Kleppe, Mensur Dzabic, Philippe Wagner, Aylin Yilmaz, Kristina Elfgren, Anders Sönnerborg, Pär Sparén, and Joakim Dillner</td>
</tr>
<tr>
<td>2669</td>
<td>A Large Cohort Study of Body Mass Index and Pancreatic Cancer by Smoking Status</td>
<td>Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Alpa V. Patel, W. Dana Flanders, and Susan M. Gapstur</td>
</tr>
</tbody>
</table>

Downloaded from cebp.aacrjournals.org on December 3, 2021. © 2020 American Association for Cancer Research.
### Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp

Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O’Connell, Mingyang Song, Kana Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor

### Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)

Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marisa Hill, Iftekhar Khan, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young

### Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States

Natalia Kunst, Fernando Aralid-Escudero, Eline Aas, Veerle M.H. Coupé, Deborah Schrag, and Karen M. Kuntz

### Genetic Variants in the Regulatory T cell–Related Pathway and Colorectal Cancer Prognosis


### Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium


### Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk


### The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology

Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley
ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, "Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review," by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.